#LCMC3 - Twitter Hashtag

over 3 years ago · Cleveland

9/@CleClinicHVTI Valerie Rusch @MSK_Thoracic #LCMC3 trial in @AATSJournals & @NatureMedicine #CheckMate816 in @NEJM ➡️ #Induction #ChemoIO Radiographic response not always predictive ➡️#ctDNA data Great tools ➡️ Need to improve #Compliance

abribriesco43's tweet photo. 9/@CleClinicHVTI
Valerie Rusch @MSK_Thoracic

#LCMC3 trial in @AATSJournals & @NatureMedicine
#CheckMate816 in @NEJM ➡️ #Induction #ChemoIO
Radiographic response not always predictive ➡️#ctDNA data
Great tools ➡️ Need to improve #Compliance https://t.co/hel7cNDRfM

1

2

0

Patrick Forde @FordePatrick

almost 4 years ago

Congratulations to Drs. @ChaftJamie & David Carbone on publication of #lcmc3 study, huge clinical and lab effort from all involved! #lcsm

Nature Medicine

@NatureMedicine

almost 4 years ago

In a single-arm, non-randomized trial, neoadjuvant #atezolizumab therapy in a large cohort of patients with resectable non-small cell lung cancer was safe and the study met its primary end point of major pathological response ≥15%. #NSCLC #NMEDclinical https://t.co/oCEsDi2Fxi

1

27

13

4

0

4

22

2

0

Zihai Li, MD, PhD @Zihai

almost 4 years ago · Upper Arlington

Very important study with provocative findings. Some innate like lymphocytes might not be good players for the ICB therapy of cancer. Congrats to Dr. David Carbone and all the #LCMC3 investigators. @OhioStatePIIO @OSUCCC_James @genentech

Pelotonia Institute for Immuno-Oncology

@OhioStatePIIO

almost 4 years ago

New data published in @NatureMedicine by Dr. David Carbone (@DCarboneMD) et al. through the LCMC3 study suggests that profiles of innate immune cells in pre-treatment peripheral blood may predict pathological response after neoadjuvant atezolizumab https://t.co/qhhNF7SNS0

0

10

0

15

3

0

Andreas Charalambous @AndreasC466

over 5 years ago

#LCMC3 Trial Primary Findings - #WCLC20 @IASLC @OncoAlert

0

6

1

0

Jose F. Corona-Cruz MD @drcoronacruz

over 5 years ago

1/3 Resultados clínicos y quirúrgicos del #LCMC3 trial, atezolizumab neoadyuvante en CP IB-IIIB. - Px que llegan a qx ➡️ 88% - Px operados en ventana de 10 d ➡️ 88%, la mayor parte de los retrasos debidos a logística y no por toxicidad. #WCLC20 @IASLC

drcoronacruz's tweet photo. 1/3 Resultados clínicos y quirúrgicos del #LCMC3 trial, atezolizumab neoadyuvante en CP IB-IIIB.

- Px que llegan a qx ➡️ 88%

- Px operados en ventana de 10 d ➡️ 88%, la mayor parte de los retrasos debidos a logística y no por toxicidad.

#WCLC20 @IASLC https://t.co/HjP3jLghxH

2

5

2

0

The Cancer Conference @TheCancerConf

over 6 years ago

Live now: Valerie Rusch, Memorial Sloan Kettering Cancer Center, New York @sloan_kettering Topic: Neo-adjuvant #immunotherapy and #surgery Speaking live from London, at @TheCancerConf Day 2 session on #Integratedcare of early stage #NSCLC #LCMC3 #lung #cancer

TheCancerConf's tweet photo. Live now: Valerie Rusch, Memorial Sloan Kettering Cancer Center, New York @sloan_kettering

Topic: Neo-adjuvant #immunotherapy and #surgery

Speaking live from London, at @TheCancerConf Day 2 session on #Integratedcare of early stage #NSCLC

#LCMC3 #lung #cancer https://t.co/9uPBPlbrOH

0

3

0

Alfredo Addeo MD @Alfdoc2

about 7 years ago

Now on Atezo in neoadjuvant in resectable NSCLC . Interim analysis of the #LCMC3 #Oncoalert

0

7

2

0

Top Tweets for #LCMC3

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users